Sound Income Strategies LLC Trims Holdings in Johnson & Johnson (JNJ)

Share on StockTwits

Sound Income Strategies LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 11.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,857 shares of the company’s stock after selling 1,257 shares during the quarter. Johnson & Johnson accounts for 0.6% of Sound Income Strategies LLC’s investment portfolio, making the stock its 19th largest position. Sound Income Strategies LLC’s holdings in Johnson & Johnson were worth $1,271,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Selective Wealth Management purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at $105,000. Fusion Family Wealth LLC grew its position in Johnson & Johnson by 621.4% during the 2nd quarter. Fusion Family Wealth LLC now owns 1,010 shares of the company’s stock worth $123,000 after purchasing an additional 870 shares during the last quarter. Ifrah Financial Services Inc. purchased a new position in Johnson & Johnson during the 3rd quarter worth $203,000. Exane Asset Management purchased a new position in Johnson & Johnson during the 2nd quarter worth $206,000. Finally, Peak Capital Management LLC purchased a new position in Johnson & Johnson during the 2nd quarter worth $207,000. Institutional investors own 67.28% of the company’s stock.

Several research analysts have issued reports on JNJ shares. Citigroup lowered their price objective on shares of Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 2nd. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $164.00 target price for the company in a research note on Wednesday, December 12th. Morgan Stanley set a $140.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Thursday, December 20th. Finally, Wells Fargo & Co reiterated an “outperform” rating and issued a $152.00 price objective (down previously from $162.00) on shares of Johnson & Johnson in a research note on Monday, January 14th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $142.81.

Shares of JNJ opened at $136.61 on Tuesday. The company has a quick ratio of 1.20, a current ratio of 1.47 and a debt-to-equity ratio of 0.46. The stock has a market cap of $367.32 billion, a price-to-earnings ratio of 16.70, a price-to-earnings-growth ratio of 2.10 and a beta of 0.68. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, January 22nd. The company reported $1.97 EPS for the quarter, topping analysts’ consensus estimates of $1.95 by $0.02. The business had revenue of $20.39 billion during the quarter, compared to the consensus estimate of $20.27 billion. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The company’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.74 earnings per share. As a group, research analysts anticipate that Johnson & Johnson will post 8.57 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 12th. Investors of record on Tuesday, February 26th were issued a $0.90 dividend. The ex-dividend date was Monday, February 25th. This represents a $3.60 dividend on an annualized basis and a yield of 2.64%. Johnson & Johnson’s payout ratio is 44.01%.

Johnson & Johnson declared that its Board of Directors has authorized a share repurchase plan on Monday, December 17th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 1.5% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

TRADEMARK VIOLATION WARNING: “Sound Income Strategies LLC Trims Holdings in Johnson & Johnson (JNJ)” was reported by Macon Daily and is the property of of Macon Daily. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://macondaily.com/2019/03/26/sound-income-strategies-llc-trims-holdings-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Economic Reports

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.